A Study of IN026 in Participants With Refractory Gout

Phase 1Not Yet RecruitingNCT07587684

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology16 enrolled

Overview

The goal of this clinical study is to learn if IN026 Injection is safe and works to lower uric acid levels in adults with refractory gout (gout that does not respond well to standard treatments). The main questions it aims to answer are: * What medical problems do participants have when taking IN026, such as changes in vital signs, blood tests, or heart rhythm? * How does the body absorb, process, and respond to IN026, and does it trigger an immune reaction? * Does IN026 lower uric acid levels in the blood and reduce tophi? Investigator will start with lower doses of IN026 and slowly increase the dose to find the well-tolerated dose. Participants will: * Receive IN026 through an intravenous (IV) drip into a vein at a set dose. * Complete a screening period of up to 4 weeks, followed by treatment and check-ups for up to 20 weeks. * Have blood and urine samples taken at set times to check safety and how the body responds to IN026.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Refractory Gout

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Can voluntarily sign the informed consent form (ICF) and comply with ICF and study protocol requirements. 2. Male or female, 18-75 years old (inclusive) at screening. 3. Meet 2015 ACR/EULAR gout classification criteria, in the intercritical phase of gout or acute flare resolved ≥2 weeks at screening. 4. Serum uric acid ≥420 μmol/L (7 mg/dl) at screening. 5. Meet the definition of refractory gout (poor uric acid control accompanied by severe gout symptoms) Exclusion Criteria: 1. Gout secondary to radiotherapy/chemotherapy, lead poisoning, organ transplantation, tumor, etc. at screening/baseline. 2. Rheumatoid arthritis, infectious/septic arthritis, or other acute inflammatory arthritis at screening/baseline. 3. Glucose-6-phosphate dehydrogenase (G6PD) deficiency history, or G6PD level below normal lower limit. 4. Positive HBsAg; HCV antibody positive is excluded except those with sustained HCV-RNA negativity after standard treatment; HIV antibody positive; active syphilis. 5. Presence of chronic liver diseases including active hepatitis, cirrhosis and alcoholic liver disease. 6. Participants with a history of any of the following: serious cardiovascular diseases within 6 months prior to screening; or serious diseases of the digestive, respiratory, urinary, musculoskeletal, neuropsychiatric, hematological, or immune systems within 3 months prior to screening. 7. Prolonged QTcF at screening. 8. Uncontrolled or untreated hypertension at screening. 9. Participants who have received medications that may affect endpoint assessment, such as other urate-lowering therapies, mRNA-LNP vaccine, PEGylated drugs and uricase agents. 10. History of severe allergy, or known allergy to IN026 or its components. 11. Participation in other clinical trials within 30 days prior to screening. 12. Participants with poor compliance, or those deemed otherwise unsuitable for this study by the investigator.

Outcomes

Primary Outcomes

Incidence of Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs)

Time frame: From first dose (Week 1 Day 1) through end of study (Week 21)

Secondary Outcomes

Change from Baseline in Serum Uric Acid Concentration

Time frame: From baseline (Week 1 Day 1) through Week 21

Change in Tophi from Baseline

Time frame: From baseline (Week 1 Day 1) through Week 21

Plasma Concentration of IN026 mRNA Over Time